F. Matonti

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Researcher

UA Monticello

Also affiliated: Thales (Portugal) (2019); Centre National de la Recherche Scientifique (2009–2025); Institut de la Vision (2014–2020); Inserm (2014–2020); Aix-Marseille Université (2008–2025); Alltech (United States) (2019); Sorbonne Université (2014–2020); Assistance Publique Hôpitaux de Marseille (2009–2023); Santé Publique France (2024); Centre Ophtalmologique d'Imagerie et de Laser (2021); Clinique Charcot (2025); Hôpital Nord (2012–2019); Clinique Saint-Joseph (2026); Laboratoire de Neurosciences Cognitives (2009–2013); Alma Consulting Group (2024–2025); Lyon Genou Centre Albert Trillat (2018–2019); Centre Azuréen de Cancérologie (2016); Délégation Provence et Corse (2021–2026); Institut de Neurosciences de la Timone (2012–2026); Clinique Saint Jean Languedoc (2015); Clinique Ambroise Paré (2025); Pro Persona (2019); Hôpital de la Timone (2006–2020); Czech Academy of Sciences, Biology Centre (2025); Egis (France) (2024)

Faculty Researcher

22 h-index 227 pubs 1,698 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

F. Matonti's research focuses on ophthalmology, particularly the management and treatment of retinal diseases and diabetic complications. This work includes investigating the efficacy and safety of various therapeutic agents, such as the fluocinolone acetonide implant and intravitreal dexamethasone implants, for conditions like diabetic macular edema and chronic diabetic macular edema. Matonti also examines surgical techniques, including the use of the NGENUITY 3D Visualization System for vitreoretinal surgery.

Further research areas encompass comparative effectiveness studies and meta-analyses of treatments for neovascular age-related macular degeneration. Matonti has also contributed to understanding the underlying biological mechanisms of diseases like diabetic retinopathy through multiomics approaches, coupling lipidomics and metabolomics profiling. Additional work involves the application of advanced technologies, such as deep learning for volumetric quantification in studies related to type 2 diabetes complications.

Matonti has published extensively in the field, evidenced by a bibliometric profile including an h-index of 22, over 226 publications, and more than 1,676 citations. The researcher is recognized as a highly cited individual. Matonti maintains an active laboratory website and has recently been active in research.